The global market for antibacterial pharmaceuticals, currently suffering from a major shift in sales from brand products to generics which has caused revenues to drop 1.8% from 2004 to 2006, is expected to experience steady growth to more than $25 billion by 2011, according to Anti-Infectives, a new report from Kalorama Information.